Vatsalya Vatsalya1,2, Akash Pandey3, Melanie L Schwandt4, Matthew C Cave5, Shirish S Barve5,6, Vijay A Ramchandani7, Craig J McClain5,6,8. 1. Department of Medicine, University of Louisville School of Medicine, 505 S. Hancock St., CTR Room 521A, Louisville, KY, 40202, USA. v0vats01@exchange.louisville.edu. 2. Laboratory of Clinical and Translational Studies, Section on Human Psychopharmacology, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA. v0vats01@exchange.louisville.edu. 3. Department of Pediatric Gastroenterology, Maria Fareri Children's Hospital - Westchester Medical Center, Valhalla, NY, USA. 4. Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA. 5. Department of Medicine, University of Louisville School of Medicine, 505 S. Hancock St., CTR Room 521A, Louisville, KY, 40202, USA. 6. Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA. 7. Laboratory of Clinical and Translational Studies, Section on Human Psychopharmacology, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA. 8. Robley Rex VA Medical Center, Louisville, KY, USA.
Abstract
BACKGROUND: Studies have reported liver injury as a consequence of antipsychotic treatment. Very heavy alcohol drinking (ten or more drinks/day for men and eight for women) also causes liver injury. This study aims to evaluate liver injury with quetiapine extended release (XR) in very heavy drinking alcohol-dependent (AD) patients. METHODS:Two hundred and eighteen AD patients, 18-65 years of age, received 12 weeks ofquetiapine XR or placebo treatment in a dose-escalated manner reaching the full dose of 400 mg/day during week 4. Blood chemistry and hematology were assessed at baseline (W0), post-titration at the end of week 3 (W4), week 8 (W8), and end of week 12 (W13). Patients were further grouped as GR.1 (no liver injury, ALT ≤40) and GR.2 (pre-existing liver injury, ALT >40) within each treatment. Drinking history, fasting blood glucose concentration (FBG), and lipid panel were used as covariates in the analyses. RESULTS:Liver injury and total drinks and average drinking measures from the Timeline follow-back questionnaire (TLFB) were highly associated. No significant exacerbation in liver injury was observed in patients treated with quetiapine XR in GR.2. Liver injury as determined by elevated alanine aminotransaminase (ALT) was reported in a few patients in GR.1 who received quetiapine XR; however, the occurrence was low, and the level of liver injury was not significant. FBG and lipid measures showed some elevation, but did not show any significant association with liver injury. CONCLUSION:Quetiapine XR did not show any significant exacerbation of liver injury in very heavy drinking alcohol-dependent patients with pre-existing liver injury. Frequency and severity of new liver injury cases in quetiapine XR-treated patients without any pre-existing liver injury was also low. Study findings support medical management of AD patients with heavy drinking profile using quetiapine XR formulation.
RCT Entities:
BACKGROUND: Studies have reported liver injury as a consequence of antipsychotic treatment. Very heavy alcohol drinking (ten or more drinks/day for men and eight for women) also causes liver injury. This study aims to evaluate liver injury with quetiapine extended release (XR) in very heavy drinking alcohol-dependent (AD) patients. METHODS: Two hundred and eighteen ADpatients, 18-65 years of age, received 12 weeks of quetiapine XR or placebo treatment in a dose-escalated manner reaching the full dose of 400 mg/day during week 4. Blood chemistry and hematology were assessed at baseline (W0), post-titration at the end of week 3 (W4), week 8 (W8), and end of week 12 (W13). Patients were further grouped as GR.1 (no liver injury, ALT ≤40) and GR.2 (pre-existing liver injury, ALT >40) within each treatment. Drinking history, fasting blood glucose concentration (FBG), and lipid panel were used as covariates in the analyses. RESULTS:Liver injury and total drinks and average drinking measures from the Timeline follow-back questionnaire (TLFB) were highly associated. No significant exacerbation in liver injury was observed in patients treated with quetiapine XR in GR.2. Liver injury as determined by elevated alanine aminotransaminase (ALT) was reported in a few patients in GR.1 who received quetiapine XR; however, the occurrence was low, and the level of liver injury was not significant. FBG and lipid measures showed some elevation, but did not show any significant association with liver injury. CONCLUSION:Quetiapine XR did not show any significant exacerbation of liver injury in very heavy drinking alcohol-dependent patients with pre-existing liver injury. Frequency and severity of new liver injury cases in quetiapine XR-treated patients without any pre-existing liver injury was also low. Study findings support medical management of ADpatients with heavy drinking profile using quetiapine XR formulation.
Authors: Raye Z Litten; Joanne B Fertig; Daniel E Falk; Megan L Ryan; Margaret E Mattson; Joseph F Collins; Cristin Murtaugh; Domenic Ciraulo; Alan I Green; Bankole Johnson; Helen Pettinati; Robert Swift; Maryam Afshar; Mary F Brunette; Nassima A-D Tiouririne; Kyle Kampman; Robert Stout Journal: Alcohol Clin Exp Res Date: 2011-09-26 Impact factor: 3.455
Authors: Donna A Wirshing; Jennifer A Boyd; Laura R Meng; Jacob S Ballon; Stephen R Marder; William C Wirshing Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: G Martinotti; M Di Nicola; R Romanelli; S Andreoli; G Pozzi; N Moroni; L Janiri Journal: Hum Psychopharmacol Date: 2007-04 Impact factor: 1.672
Authors: Keming Gao; Renrong Wu; David E Kemp; Jun Chen; Elizabeth Karberg; Carla Conroy; Philip Chan; Ming Ren; Mary Beth Serrano; Stephen J Ganocy; Joseph R Calabrese Journal: J Clin Psychiatry Date: 2014-10 Impact factor: 4.384
Authors: Howard C Margolese; Leslie Malchy; Juan Carlos Negrete; Raymond Tempier; Kathryn Gill Journal: Schizophr Res Date: 2004-04-01 Impact factor: 4.939